Stoke Therapeutics filed a prospectus supplement to offer and sell up to $200 million of common stock under an existing at-the-market equity offering agreement with Cantor Fitzgerald. This filing updates the automatic shelf registration statement previously established in March 2026. The company operates in the biotechnology industry, focusing on developing treatments for genetic diseases.
